文献速递肿瘤 PET/CT

使用[18F]PSMA-1007 PET/CT进行原发性前列腺癌分期时转移性疾病的风险

Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging.
PubMed 文献 · EJNMMI Res · 2021-12-20

该回顾性研究纳入194例经病理确诊的前列腺癌患者,于2019年5月至2020年5月间行[18F]PSMA-1007 PET/CT原发分期,评估临床变量与影像学特征的关系。结果显示转移性疾病与ISUP分级及PSA水平相关,原发肿瘤SUVmax与ISUP分级、PSA水平及AJCC分期相关。

要点

  • ISUP分级与总体转移、区域淋巴结、非区域淋巴结及骨转移均相关。
  • PSA水平与总体转移、区域及非区域淋巴结转移相关,与骨转移无关。
  • 原发肿瘤SUVmax与ISUP分级、PSA水平及AJCC分期相关。

核心结论

  • 根据[18F]PSMA-1007 PET/CT检出的转移性疾病与ISUP分级和PSA水平相关。
  • 这是使用[18F]PSMA-1007 PET/CT的最大样本研究,证实PSA水平、ISUP分级和分期与原发前列腺肿瘤SUVmax呈正相关。

研究设计与样本

  • 回顾性审查2019年5月至2020年5月间连续纳入的194例经组织病理学确诊为前列腺癌并接受[18F]PSMA-1007 PET/CT原发分期的患者。
  • 采用描述性统计、逻辑回归模型和ROC分析评估影像学变量(转移性疾病的存在与分布、原发肿瘤SUVmax)与临床变量(EAU风险标准)之间的关联。

主要发现

  • 中位年龄70岁,中位PSA水平10 ng/mL,中位ISUP分级为3级。
  • 36.6%的患者为中危,60.8%的患者为高危。
  • ISUP分级与总体转移(p=0.008)、区域淋巴结转移(p=0.003)、非区域淋巴结转移(p=0.041)及骨转移(p=0.006)相关。
  • PSA水平与总体转移(p=0.001)、区域淋巴结转移(p=0.001)及非区域淋巴结转移(p=0.004)相关,与骨转移无关(p=0.087)。
  • 原发前列腺肿瘤SUVmax与ISUP分级(p=0.004)、PSA水平(p<0.001)及AJCC分期(p=0.034)相关。

关键数值与推荐

  • PSA>20 ng/mL检测转移性疾病的特异性为85%(95%CI 78-91%),敏感性为36%(95%CI 25-49%)。
  • ISUP分级>3检测转移性疾病的特异性为60%(95%CI 50-68%),敏感性为62%(95%CI 49-74%)。
  • 内脏转移病例过少,无法进行有意义的分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 内脏转移病例过少,无法进行有意义的分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate prostate cancer imaging is critical for patient management. Multiple studies have demonstrated superior diagnostic accuracy of [68Ga]-PSMA-11 PET/CT over conventional imaging for disease detection, with validated clinical and biochemical predictors of disease detection. More recently [18F]PSMA-1007 offers theoretical imaging advantages, but there is limited evidence of clinical and biochemical predictors of scan findings in the staging population. This study investigates the association of clinical variables with imaging characteristics among patients who underwent [18F]PSMA-1007 PET/CT for primary staging of men with histopathologically confirmed prostate carcinoma. A retrospective review of 194 consecutive patients imaged between May 2019 to May 2020 was performed. Association between imaging variables (presence and distribution of metastatic disease, primary tumour SUVmax) and clinical variables (EAU risk criteria) were assessed using descriptive statistics, logistic regression model and ROC analysis. RESULTS: The median age, PSA level and ISUP grade were 70 years, 10 ng/mL and ISUP grade 3, respectively. There were 36.6% of patients with intermediate-risk and 60.8% of patients with high-risk disease. ISUP grade was associated with the presence of metastasis overall (p = 0.008) as well as regional nodal (p = 0.003), non-regional nodal (p = 0.041) and bone (p = 0.006) metastases. PSA level was associated with metastatic disease overall (p = 0.001), regional (p = 0.001) and non-regional nodal metastases (p = 0.004), but not with bone metastases (p = 0.087). There were too few visceral metastases for meaningful analysis. SUVmax of the primary prostatic tumour was associated with ISUP grade (p = 0.004), PSA level (p < 0.001) and AJCC stage (p = 0.034). PSA > 20 ng/mL and ISUP grade > 3 had a specificity of 85% (95% CI 78-91%) and 60% (95% CI 50-68%) and a sensitivity of 36% (95% CI 25-49%) and 62% (95% CI 49-74%), respectively, for detection of metastatic disease. CONCLUSION: Metastatic disease according to [18F]PSMA-1007 PET/CT was associated with ISUP grade and PSA level. This is the largest study using [18F]PSMA-1007 PET/CT to confirm a positive correlation of PSA level, ISUP grade and stage with primary prostate tumour SUVmax.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chikatamarla VA, Okano S, Jenvey P, et al. Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. EJNMMI Res. 2021. PMID: 34928437. doi:10.1186/s13550-021-00869-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。